14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BCAX vs MBX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, MBX Biosciences, Inc. (MBX) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.58 (N/M Forward P/E, 0.0% operating margin), whereas MBX carries 44.9/100 (HOLD) at $53.54 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While BCAX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. MBX 44.9/100 HOLD), MBX captures the overall institutional head-to-head verdict (4–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile MBX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs MBX. Trailing 12-month operating profitability (BCAX 0.0% vs MBX 0.0%) and valuation multiples (BCAX N/M vs MBX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.7B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BCAX vs MBX Key Questions & Quantitative Answers
As of Nov 16, 2026, MBX Biosciences, Inc. (MBX) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.58 (N/M Forward P/E, 0.0% operating margin), whereas MBX carries 44.9/100 (HOLD) at $53.54 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While BCAX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. MBX 44.9/100 HOLD), MBX captures the overall institutional head-to-head verdict (4–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile MBX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MBX leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MBX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus N/A for MBX. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MBX.
BCAX and MBX trade at balanced relative valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus MBX (-33.7% ROE) capital efficiency.
In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 184% Vol realized risk). By comparison, MBX carries 64.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.58β · 66% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.